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1Department of Pulmonary Medicine, Erasmus MC Rotterdam, the Netherlands; 2Erasmus MC Cancer Institute, Erasmus MC Rotterdam, the NetherlandsDendritic cells (DCs) are the most potent antigen-presenting
cells and are the key initiator of tumor-speciﬁc immune re-
sponses. These characteristics are exploited by DC therapy,
where DCs are ex vivo loaded with tumor-associated antigens
(TAAs) and used to induce tumor-speciﬁc immune responses.
Unfortunately, clinical responses remain limited to a propor-
tion of the patients. Tumor characteristics and the immuno-
suppressive tumor microenvironment (TME) of the tumor
are likely hampering efﬁcacy of DC therapy. Therefore,
reducing the immunosuppressive TME by combining DC ther-
apy with other treatments could be a promising strategy.
Initially, conventional cancer therapies, such as chemotherapy
and radiotherapy, were thought to speciﬁcally target cancerous
cells. Recent insights indicate that these therapies additionally
augment tumor immunity by targeting immunosuppressive
cell subsets in the TME, inducing immunogenic cell death
(ICD), or blocking inhibitory molecules. Therefore, combining
DC therapy with registered therapies such as chemotherapy,
radiotherapy, or checkpoint inhibitors could be a promising
treatment strategy to improve the efﬁcacy of DC therapy. In
this review, we evaluate various clinical applicable combination
strategies to improve the efﬁcacy of DC therapy.https://doi.org/10.1016/j.omto.2019.03.007.
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E-mail: h.vroman@erasmusmc.nlDendritic cells (DCs) are professional antigen-presenting cells (APCs)
capable of inducing a potent immune response through the presenta-
tion of exogenous antigens.1 Immature DCs, efﬁcient at engulﬁng and
processing antigens, reside in the periphery, and they mature upon
encounter with danger-associated molecular patterns (DAMPs) and
pattern-associated molecular patterns (PAMPs).2 Upon encounter
with these danger signals, DCs upregulate co-stimulatory molecules
(CD80, CD86, andCD40) and chemokine receptors (e.g., CCR7), pro-
duce pro-inﬂammatory cytokines, and migrate to the lymph node to
activate T cells.3 T cell activation is induced by antigen presentation
(signal 1), co-stimulation (signal 2), and the secretion of pro-inﬂam-
matory cytokines (signal 3).4 In contrast, antigen presentation in the
absence of signals 2 and 3 induces tolerance.5,6 In a tumor setting,
both tumor cells and immunosuppressive cells in the tumor microen-
vironment (TME) can hamper anti-tumor immune responses.7
In DC therapy production, DCs are loaded and matured ex vivo to
circumvent the initial immunosuppressive inﬂuence of the TMEMolecu
This is an open access article underand tumor cells on endogenous DC maturation. In addition, the
administration of autologous DCs could induce and improve in vivo
tumor-speciﬁc immune response. It is believed that DC therapy has
not yet reached its full potential.8–10 The rather limited clinical efﬁ-
cacy of DC therapy can be dependent on DC therapy-related aspects,
such as the choice of antigen, method of loading, or type of DCs used.
Next to that, active immunosuppression by the tumor and the TME
could also hamper the immune-activating potential of the adminis-
tered DCs and suppress the function and inﬁltration of activated
T cells.11–13
Therefore, targeting these immunosuppressive features of the TME
using FDA-approved treatment modalities, such as chemotherapy,
radiotherapy, or more recently developed checkpoint inhibitors
(CIs), in combination with DC therapy could improve DC therapy
efﬁcacy1,7,8,12,14–17 (Figure 1). In this review, we discuss the immuno-
logical barriers that DC therapy faces and potential synergistic
immunomodulating treatment modalities. In addition, we review
clinical trials that have combined DC therapy with additional treat-
ments. Data regarding these conducted clinical trials were found us-
ing a search string of relevant terms, as described in the Supplemental
Information.Immunosuppressive Mechanisms of the TME and Tumor Cells
that Hamper the Efficacy of DC Therapy
Both tumor cells and immunosuppressive immune cells in the TME
hamper the effectivity of DC therapy through various mechanisms,
such as the expression of inhibitory molecules, secretion of inhibitory
cytokines or enzymes, induction of tolerogenic cell death, and crea-
tion of a dense extracellular matrix.18,19 Tumor cells recruit immuno-
suppressive immune cells, ﬁbroblasts,20 and endothelial cells to the
TME through the secretion of growth factors, chemokines,
and cytokines, thereby hampering the inﬁltration of DCs and other
pro-inﬂammatory cells into the TME.21,22 Moreover, ﬁbroblasts and
immunosuppresive immune cells interact synergistically with each
other to maximize the immunosuppressive character of the TME.lar Therapy: Oncolytics Vol. 13 June 2019 ª 2019 The Author(s). 67
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Targeting the TME with Conventional Treatment Modalities
(A) Inhibitory molecules (PD-(L)1, CTLA-4) inhibit T-cell effector, dendritic cell and natural killer (NK)-cell function, and T-cell activation in the lymphnode. Checkpoint inhibitors
targeting (PD-(L)1, CTLA-4) can reinvigorate the anti-tumor immune response induced by dendritic cell (DC) therapy by blocking PD-(L)1 signaling in the tumor and CTLA-4 in
the lymph node. (B) Regulatory T cells (Tregs) exert their immunosuppressive mechanisms through inhibitory molecules (CTLA-4), secretion of immunosuppressive cytokines
(interleukin [IL]-10, TGFb), and IL-2 consumption, thereby inhibiting NK-cells, T cells, and DCs and skewing tumor-associated macrophages (TAMs) in a unfavorable M2
phenotype. Tregs can be depleted with several chemotherapeutics (cyclophosphamide, paclitaxel, docetaxel, gemcitabine, temozolamide, and oxaliplatin). (C) Myeloid-
derived suppressor cells (MDSCs) can exert their immunosuppressive function by relieving Arginase 1 (Arg1) and inducible nitric oxide synthase (iNOS) to deprive T cells of
metabolites. MDSCs can be depleted by chemotherapeutics gemcitabine, 5-FU, cisplatin, and docetaxel and skewed into a M1 phenotype by docetaxel. (D) M2 TAMs
secrete IL-10 and transforming growth factor b (TGF-b) and are involved in tissue remodeling, wound healing, and tumor progression. M2 TAMs can be depleted by CSF-1R
and skewed into an M1 phenotype by CD40 agonists. (E) Immunogenic cell death (ICD) is characterized by secretion of ATP and high mobility group box 1 (HGMB-1) and
expression of Calreticulin (CRT) on the cell surface, which stimulates DC phagocytosis, antigen presentation, and migration. ICD can be induced by chemotherapeutics,
cyclophosphamide, oxaliplatin, paclitaxel, docetaxel and anthracyclines, and radiotherapy.
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Cancer cell death can be tolerogenic or immunogenic depending on
the stimulus of apoptosis.23 Immunogenic cancer cell death leads to
the secretion of DAMPs, attracts pro-inﬂammatory cells, and subse-
quently elicits a tumor-speciﬁc immune response (Box S1). Non-
immunogenic cell death of malignant cells occurs without secretion
of pro-inﬂammatory DAMPs. Tumor cells undergo non-immuno-
genic cell death through chemo-attraction of immunosuppressive
phagocytes and induction of immunosuppressive phagocytosis.24
Tumor cells actively impair DC maturation through the secretion
of immunosuppressive cytokines, leading to the presentation of tu-
mor-associated antigens (TAAs) by immature DCs. Presentation of
antigens by immature DCs induces T cell anergy and activation of
TAA-speciﬁc regulatory T cells (Tregs), resulting in TAA-speciﬁc
tolerance.1,25–27
Tregs
Tregs are recruited to the TME through CCR4 chemokine signaling,
and they expand in the TME upon transforming growth factor b
(TGF-b) and interleukin (IL)-10 exposure.28 Tregs enable tumor pro-
gression by suppressing tumor-speciﬁc immune responses. In gen-
eral, Tregs induce immunosuppression directly through cell-cell
contact via inhibitory receptors, such as programmed cell death 1
(PD-1) or cytotoxic T-lymphocyte associated protein 4 (CTLA-4),
or indirectly through the secretion of immunosuppressive cytokines,
such as IL-10 and TGF-b, or IL-2 consumption of pore-forming pro-
teins, such as granzyme and perforin.29 Via these mechanisms, Tregs
suppress a wide array of pro-inﬂammatory immune cells that can be
induced upon DC therapy, such as CD8+ T cells, CD4+ T cells, natural
killer (NK) cells, NK T cells, and B cells. Additionally, Tregs can also
suppress macrophages and DCs, thereby hampering the induction of
an initial anti-tumor immune response.8,14 Moreover, tumor-inﬁl-
trating Tregs have a higher afﬁnity to TAAs derived from self-anti-
gens presented on tumor cells than CD8+ T cells, thereby affecting
the activation of TAA-speciﬁc CD8+ T cells in the TME.22 The
Treg functions create a hostile and competitive environment for
DC therapy-induced tumor-speciﬁc CD8+ T cells, hindering their
cytotoxic functions.
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are immature myeloid
cells with immunosuppressive effects. MDSCs are one of the most
abundant immune cells in the TME, and they are attracted to the tu-
mor site by chemokines secreted by the tumor cells.30–32 MDSCs
comprise two subsets: monocytic MDSC (mMDSC) and polymor-
phonuclear MDSC (pMDSC).33,34 mMDSCs tend to be more
immunosuppressive than pMDSCs, as they are capable of both anti-
gen-dependent and antigen-independent inhibition of T cell re-
sponses.18,35 The hypoxic environment of the TME induces the
release of hypoxia-inducible factor 1-alpha (HIF-1a), which causes
mMDSCs to upregulate the enzymes arginase 1 (Arg1) and inducible
nitric oxide synthase (iNOS) that break down L-arginase.35 Two
products of this enzymatic reaction, urea and nitric oxide (NO),
induce T cell depletion and inhibit T cell function.18,31,36,37 Moreover,mMDSCs attract Tregs through C-C motif chemokine ligand 2
(CCL4) and CCL5 production, secrete IL-10,38 and upregulate PD-
L1 on their cell surface, which inhibits tumor-speciﬁc T cell cytotox-
icity.39 Furthermore, HIF-1a induces differentiation of mMDSCs into
tumor-associated macrophages (TAMs) through the downregulation
of phosphorylated signal transducer and activator of transcription 3
(pSTAT3), indicating that the TME can inﬂuence both immune cell
function and differentiation.40,41
TAMs
Monocytes are derived from the bone marrow and are recruited to the
TME through CCL2 signaling, where these cells can differentiate into
macrophages. Phenotypically, macrophages can broadly be divided
into two subtypes: a pro-inﬂammatory M1 phenotype and an immu-
nosuppressive M2 phenotype. Differentiation of M1 macrophages is
induced by pro-inﬂammatory cytokines such as interferon (IFN)-g
and bacterial components such as lipopolysaccharide (LPS). M1mac-
rophages secrete pro-inﬂammatory cytokines, interleukins such as IL-
12, and tumor necrosis factor a (TNF-a), leading to inﬂammation.19
Macrophages are skewed into an M2 phenotype, through the secre-
tion of immunosuppressive cytokines by tumor cells or immune cells
in the TME, and they inhibit CD8+ T cell function.41 TAMs display an
M2-like phenotype and secrete IL-10, prostaglandin E2 (PGE2), and
chemokines to attract and induce Tregs.18,41 Moreover, TAMs ex-
press iNOS and Arg1, and they upregulate PD-L1 on their cell surface,
which inhibits CD8+ T cell function.18,42 These mechanisms hamper
DC therapy-induced anti-tumor immunity.
DC Therapy
Different DC Therapy Strategies
DC therapy aims at eliciting a tumor-speciﬁc immune response, by
in vitro loading DCs in vitro with tumor antigens and additional
maturation stimuli. DC therapy can be historically divided into three
categories: ﬁrst-, second-, and next-generation DC therapy.1 In ﬁrst-
and second-generation DC therapy, monocyte-derived DCs (moDCs)
were used. moDCs are generated from monocytes upon culture with
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
IL-4. moDCs have been shown to promote T cell differentiation
and CD8+ T cell activation.43 In ﬁrst-generation DC therapy, moDCs
were loaded with a tumor lysate, TAAs, or synthetic peptides without
additional maturation stimuli. Not surprisingly, without a proper
maturation stimulus, clinical results were disappointing, with a tumor
regression rate of 3.3%.44
In second-generation DC therapy, moDCs were additionally matured
after loading these immature moDCs, using maturation cocktails,
including IL-6, TNF, IL-1b, PGE2, and polyinosinic:polycytidylic
acid (poly(I:C)).45 Maturing these tumor antigen-loaded moDCs
signiﬁcantly improved clinical results, with overall response rates
(ORRs) of 8%–15%, depending on the tumor type.9 Median overall
survival (OS) was increased by 20% in multiple clinical trials with sec-
ond-generation DC therapy, which is the threshold for clinical rele-
vance.9,45,46 Furthermore, the IMPACT trial showed an increase in
median OS of 3.9 months for castration-resistant prostate cancerMolecular Therapy: Oncolytics Vol. 13 June 2019 69
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cebo group, leading to FDA approval in 2010.47
In next-generation DC therapy, naturally occurring DCs (nDCs),
such as plasmacytoid DCs (pDCs) and conventional DCs (cDCs),
are used for vaccination. cDCs can be divided into twomain subtypes:
cDC1 and cDC2.48 cDC1s are superior in cross-presenting antigens
and, thereby, inducing CD8+ T cell activation. Recent studies have
shown that cDC1s are critically important for anti-tumor immune re-
sponses and that their presence in the TME positively correlates to OS
and clinical responses upon PD-1 monoclonal antibody (mAb) in
melanoma.49–51 Classically, cDC2s mainly activate CD4+ T cells.
The characterization of human cDC2 function remains difﬁcult, as
this subset is very heterogeneous, shares markers such as CD11b
and CD172a with macrophages andmoDCs, and has functional over-
lap with cDC1s.50 pDCs in the TME produce type 1 IFN, which
attracts NK, B, and T cells.52 However, pDCs have questionable anti-
gen-presenting skills, as CD123+ pDCs were found to be contami-
nated with pre-cDCs.53 Naturally occurring DCs can, therefore, be
selected based on their superior functional properties, and they can
be obtained without an additional culture period, leading to reduced
production costs.1
DCs can also be targeted in vivo using Toll-like receptor (TLR) li-
gands, intra-tumoral injection of TriMix mRNA, or attenuated viral
agents (virotherapy).54–56 Furthermore, FMS-like tyrosine kinase 3
ligand (FLT3L) injection increases cDC proliferation and inﬁltration
into the tumor site, which enhanced PD-L1 mAb efﬁcacy in a mela-
nomamouse model.57,58 Clinical trials exploiting next-generation DC
therapy are currently being performed, and the coming years will
indicate whether the use of nDCs further improves the clinical efﬁ-
cacy of DC therapy.59,60 Currently, clinical studies comparing the
effectivity of different DC subtypes for vaccination purposes are lack-
ing and are urgently needed to determine which DC subset would
induce the most effective anti-tumor immune response.61
Immune Monitoring
Immunological responses induced by DC therapy are generally
measured by IFN-g enzyme-linked immunospots (ELISPOTs),
tetramer analysis, co-cultures with lysate-loaded DCs, and delayed
type hypersensitivity (DTH) skin tests. Correlating these immunolog-
ical parameters to clinical response remains challenging, as not all
patients show increased IFN-g production in an ELISPOT upon
DC therapy, and even positive ELISPOTs can be encountered
before DC therapy.62,63 Furthermore, tumor-speciﬁc IFN-g produc-
tion by peripheral blood mononuclear cells (PBMCs), as determined
by an ELISPOT analysis, often does not correlate with clinical
outcome or allergic reaction measured by the DTH skin test.62,64,65
However, in some studies, immunological parameters have been
correlated with clinical parameters in both hematological and solid
malignancies.59,66,67
DTH skin tests have been shown to correlate with clinical outcome in
DC therapy trials in melanoma and colorectal cancer patients.68–7070 Molecular Therapy: Oncolytics Vol. 13 June 2019Furthermore, in mesothelioma patients treated with DC therapy,
two patients with a negative DTH skin test had progressive disease
and had the shortest OS,71 indicating that the DTH skin test could
correlate with clinical outcomes. Additionally, in pancreatic cancer
patients treated with Wilms tumor protein 1 (WT1) I-II peptide-
loaded DC therapy, positive DTH skin tests correlated with longer
progression-free survival (PFS) and OS than negative DTH skin
tests.72 However, all other studies combining DC therapy and chemo-
therapy did not show any correlation between DTH skin testing and
clinical outcome.62,64,65,72–74 The lack of correlation between DTH
skin tests with clinical outcome could be dependent on the timing
of the DTH skin test, the evaluation of response to the skin test,
and the lack of a negative control. The classiﬁcation of a positive
DTH skin test varies from 2- to 5-mm erythema, while one could
argue that induration is a more important parameter.75 Also timing
of DTH skin testing varies between studies or is not mentioned.
Combination Strategies to Optimize DC Therapy
Combining CIs with DC Therapy
Inhibitory molecules that hamper anti-tumor immune responses,
such as PD-1, PD-L1, and CTLA-4, can be expressed on both tumor
cells and various immune cells.76,77 Blocking these inhibitory mole-
cules has been shown to restore tumor-speciﬁc T cell activity.76 There
are many other inhibitory and even co-stimulatory molecules identi-
ﬁed that could function as potential targets for immunotherapy, such
as lymphocyte activation gene-3 (LAG-3), B and T lymphocyte atten-
uator (BTLA), programmed death-1 homolog (PD-1H), T cell immu-
noglobulin (TIM-3), T cell immunoglobulin and immunoreceptor
tyrosine-based inhibitory motif domain (TIGIT), glucocorticoid-
induced TNF receptor (GITR), and NK cell inhibitory receptor
NKG2A.78–82 The efﬁcacy of these co-inhibitory and co-stimulatory
molecules is currently being investigated in preclinical and/or clinical
studies, and it is, therefore, not addressed in this review.
CTLA-4 blockage inhibits T cell activation in the lymph node,
whereas blocking the PD-1 and PD-L1 axis mainly inhibits the
effector function of activated T cells in the TME.83 Anti-CTLA-4 (ipi-
limumab and durvalumab), anti-PD-L1 (atezolizumab, durvalumab,
and avelumab), and anti-PD-1 (nivolumab and pembrolizumab)
are registered for the treatment of solid tumors, because of striking
clinical effects. The efﬁcacy of these CIs, especially PD-(L)1 mAb,
often depends on and correlates with PD-L1 expression in the
TME, mutational burden, and the number of tumor-inﬁltrating lym-
phocytes (TILs).13,84–87 High ORRs of 57% are reported in immuno-
genic cancers such as melanoma, which is ascribed to a high muta-
tional burden and high numbers of TILs.88,89 In tumors with lower
mutational burden (e.g., mesothelioma), ORRs remain between 9%
and 25%,90 likely due to the relative low frequency of TILs. DC ther-
apy induces the inﬁltration of tumor-speciﬁc CD8+ T cells and upre-
gulates PD-1 expression on these TILs, which could render tumors
with low TIL numbers susceptible to anti-PD-(L)1 treatment.91–94
It is likely that the limited efﬁcacy of DC therapy trials is in part due to
inhibitory signaling in the TME and lymph node. Additional
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and immunosuppressive cells in the TME. CIs could even inhibit
the signaling of these inhibitory molecules on the DCs administered
during DC therapy, as DCs express PD-1, PD-L1, and PD-L2.95
Expression of PD-1 and its ligands likely limits the induction of tu-
mor-speciﬁc immune responses, as high PD-L1 expression on DCs
suppresses CD4+ and CD8+ T cell proliferation and promotes Treg
proliferation in various diseases, including cancer.8,96–101 This sug-
gests that combining DC therapy with CIs can result in a two-sided
synergy by targeting not only tumor cells and immunosuppressive
cells in the TME but also DCs administered during DC therapy and
even T cells induced by DC therapy (Figure 1A). Different DC sub-
types differentially express these inhibitory molecules, suggesting
that speciﬁc CIs should be used in combination with certain DC sub-
sets.102 The rationale for using CIs in combination with DC therapy is
further supported by the ﬁnding that the addition of a PD-1 mAb to
ex vivo-cultured autologous T cells and DCs of patients withmyeloma
improved IFN-g production while limiting Treg expansion.103
Furthermore, combining DC therapy with systemic PD-1 blockade
in mice bearing intracranial glioma tumors improved survival
compared to both single treatments.91 In addition, PD-1 blockage
on DCs, administered in a breast tumor-bearing mouse model, that
were subsequently systemically treated with anti-PD-1 mAb reduced
tumor growth and increased survival compared to untreated mice.104
Clinical Trials Combining CIs with DC Therapy
Until now, three clinical studies combined DC therapy with CI treat-
ment. In all of these studies, CTLA-4 mAb has been used. Clinical re-
sponses were retrospectively observed in patients with stage III and IV
melanoma that were treated with ipilimumab upon disease progres-
sion, after receiving at least 3 bi-weekly vaccinations with gp100
and tyrosinase-loaded DCs.105 Especially patients with stage III mel-
anoma responded well, with an OS rate of 51% after 2 years. The pres-
ence of tumor-speciﬁc T cells obtained from DTH skin biopsies did
not correlate to OS in patients with stage III and IV melanoma.
Ipilimumab-related adverse events were not increased in patients pre-
treated with DC vaccination (58%) compared to patients treated with
ipilimumab monotherapy (61%–70%).106
In a clinical phase I, dose escalation trial, patients with stage IIIc or IV
melanoma received three bi-weekly intradermal vaccinations with
MART-1-loaded DCs and concurrent systemic treatment with a
dose escalation of tremelimumab (3, 6, and 10 mg/kg), a CTLA-4-
blocking mAb.107 Four of 16 patients developed a clinical response
upon treatment, of which 2 patients developed a complete response
(CR) and 2 patients developed a partial response (PR). This
indicates that response rates upon combination therapy are prom-
ising, compared to response rates to tremelimumab monotherapy
(7%–10% ORR)107–110 and DC vaccination monotherapy (15%
ORR).9 Remarkably, responses were also observed in patients treated
with only 3 mg/kg tremelimumab, achieving plasma levels of
30 mg/mL, which is below the target level determined by prospective
clinical trials.108 This suggests that these results are not solely the ef-
fect of tremelimumab or DC therapy alone, indicating a synergisticeffect. However, immunological analysis was inconclusive, with a mi-
nority of patients showing a response to tetramer or ELISPOT
analysis.108
A phase II, open-label, single-arm clinical trial combined ipilimumab
treatment with DCs electroporated with Trimix-mRNA (CD40L,
CD70, constitutive active TLR4) and mRNA encoding for MAGE-
A3, MAGE-C2, tyrosinase3, or gp100 in patients with stage III and
IV melanoma.111 Radiological responses were assessed with im-
mune-related response criteria (irRCs), which showed an ORR of
38%; 20% of the responding patients showed a CR and 18% had a
PR. A disease control rate of 51% at 6-month follow-up was observed,
and the ORR was better than ORRs observed in patients treated with
ipilimumab as monotherapy.112 Furthermore, the number of CRs was
similar to clinical trials investigating combination therapy of ipilimu-
mab and nivolumab.106 Immunological analysis showed an overall
increase of CD4+ and CD8+ T cells in the peripheral blood and a
positive tumor antigen-speciﬁc ELISPOT analysis in two of ten
patients.111
Combining different CIs often leads to increased toxicity, such
as dermatologic toxicity, colitis, or pneumonitis,113,114 whereas
combining DC therapy with CIs does not increase the immune-
related adverse event proﬁle of CI monotherapy. Furthermore,
ORRs, PFS, and OS in clinical trials investigating combination ther-
apy consisting of DC therapy and CTLA-4 mAb treatment are prom-
ising, as compared to clinical trials that investigated these therapies as
monotherapy. However, phase III, randomized, controlled clinical
trials are needed to determine the efﬁcacy improvement of combining
DC therapy and CI to either treatment modality alone. Furthermore,
combining PD-(L)1-targeting CIs with DC therapy still needs to
be evaluated in clinical trials. Immunological analysis was inconclu-
sive in all studies and did not correlate with clinical outcome. Concur-
rent intensive immunological analysis of blood and tumor material
could provide proof of principle, expand current knowledge, and
possibly lead to objectiﬁable immunological parameters for immuno-
therapy. Currently, many phase I-II trials are being conducted
that combine PD-(L)1 mAb with DC therapy.56,115 However, to
date, there are no clinical phase III trials being conducted to
observe the synergy of CI treatment in combination with DC therapy
(https://clinicaltrials.gov/).
Combining Chemotherapy with DC Therapy
Apart from speciﬁcally targeting cancerous cells, it is becoming
apparent that chemotherapy can also actively inﬂuence the immune
system by depletion of speciﬁc cell types, such as Tregs and MDSCs,
and by induction of immunogenic cell death (ICD). Furthermore,
chemotherapy can skew immunomodulatory cells in a more pro-in-
ﬂammatory subset. Depletion of Tregs12 and MDSCs116 in the TME
after chemotherapy treatment was already observed in preclinical
and clinical studies.11,12,17,23,117,118 Such immunological changes
were even associated with clinical response.118–122 Furthermore,
ICD-inducing chemotherapy, such as anthracyclines, has a subopti-
mal result in immunodeﬁcient mice.23,123 This indicates thatMolecular Therapy: Oncolytics Vol. 13 June 2019 71
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cell-speciﬁc depletion and improve immune responses by the induc-
tion of ICD, thereby proving beneﬁcial when combined with DC
therapy.
In most clinical trials, DC therapy was administered in combination
with registered chemotherapy treatment. Therefore, studies that com-
bined treatment of chemotherapeutics with DC therapy were not
often designed to improve DC therapy efﬁcacy. Consequently, most
of the immunological parameters, such as IFN-g ELISPOTs, tetramer
analysis, and DTH skin tests, determined immunological response to
DC therapy rather than the immunological effects induced by chemo-
therapy.62,63,65,72,124,125 Consequently, monitoring of immunomodu-
latory effects and, therefore, objectifying the attributable effect of
chemotherapy on DC therapy is difﬁcult to achieve. Clinical trials
that investigated treatment with DC therapy in combination with
chemotherapy in esophageal, prostate, and pancreatic cancers; meso-
thelioma; glioblastoma; and melanoma are summarized in Table 1.
Targeting of the Immunosuppressive Environment by
Chemotherapy
Tregs. Various chemotherapeutics, such as cyclophosphamide,
paclitaxel, docetaxel, gemcitabine, temozolamide (TMZ), and oxali-
platin, are capable of Treg depletion in clinical and preclinical set-
tings.12,17,117,118,126 Cyclophosphamide is the best known and studied
chemotherapeutic agent with the capability of depleting Tregs. Four
clinical studies evaluated the immunological and clinical effects of
potentially Treg-depleting chemotherapeutics in combination with
DC therapy, in which 3 studies used cyclophosphamide64,71,73 and
one study used TMZ.74 Two other studies evaluated only clinical ef-
fects of potentially Treg-depleting chemoteherapeutics, cyclophos-
phamide and paclitaxel, in combination with DC therapy.
In a phase I clinical trial, melanoma patients were treated with six
biweekly injections of DCs electroporated with mRNA encoding
p53, survivin, and hTER and concurrent low-dose cyclophosphamide
(2  50 mg/day biweekly).127 The OS was 10.4 months and 9 of 22
patients had stable disease (SD). Tregs as well as total CD4+ T cells
were depleted upon cyclophosphamide treatment, questioning
whether cyclophosphamide induced speciﬁc depletion of Tregs.127
However, another clinical trial in mesothelioma patients that also
combined concurrent low-dose cyclophosphamide (2  50 mg/day
biweekly) with three biweekly injections of DCs loaded with tumor
lysate did show selective depletion of Tregs.71 Unfortunately, deple-
tion of Tregs was not correlated with a better clinical outcome. How-
ever, detailed analysis of naive Tregs (nTregs, CD45RA+ FoxP3int)
and activated Tregs (aTregs, CD45RA FoxP3hi) showed a positive
correlation between the pretreatment levels of nTregs and OS.128 In
addition, results from this clinical study are quite promising, with pa-
tients still alive up to 6 years after diagnosis.
Another phase II clinical study combined DC therapy loaded with tu-
mor lysate or peptides (surviving, telomerase and p53) with consecu-
tive IL-2 (2 million international units [mIUs]/day for 5 days) with72 Molecular Therapy: Oncolytics Vol. 13 June 2019metronomic cyclophosphamide (2  50 mg/day biweekly) and a
Cox-2 inhibitor (200 mg daily) in melanoma patients.73 Melanoma
patients treated with this combination therapy also showed increased
numbers of Tregs after four vaccinations, indicating that cyclophos-
phamide was not able to counteract the effect of IL-2 on Tregs, as
IL-2 has the potency to increase Treg numbers.129 In contrast to
Tregs, mMDSCs were signiﬁcantly decreased after four vaccinations,
indicating that the combination treatment depletes mMDSCs. How-
ever, the changes observed in Treg numbers and mMDSC frequency
did not correlate with clinical outcome. Clinical results were signiﬁ-
cantly improved compared to a previous trial where DC therapy
was only combined with IL-2.130
Combining neoadjuvant TMZ (75 mg/m2/day for 14 days) treatment
followed by autologous tumor lysate-loaded DC therapy with consec-
utive IL-2 (3 mIU/day for 5 days) in 17 melanoma patients, also
signiﬁcantly depleted Tregs, although this did not correlate to clinical
outcome. One patient showed a PR and six patients had SD.74
In another study, patients with metastatic castration-resistant pros-
tate cancer were treated with neoadjuvant metronomic cyclophos-
phamide (50 mg/day for 1 week) followed by LNCaP- (androgen-
sensitive human prostate adenocarcinoma cells) loaded DC therapy
and docetaxel (75 mg/m2 every 3 weeks). The predicted OS was
11.3 months, whereas in this study an OS of 19 months was observed,
suggestive of a synergistic effect upon the combination of these
treatments.131,132
In a clinical trial in patients with stage IVmelanoma treated with DCs
loaded with a multi-peptide (WT1, gp100, tyrosinase, and MAG-E3
or MAGE-A2) combined with paclitaxel (175 mg/m) and carboplatin
(area under the curve 5), an OS of up to 24 months was observed.124
Unfortunately, Treg numbers were not assessed in these clinical trials.
Taken together, these clinical trials indicate that chemotherapy is
capable of depleting Tregs and inducing promising clinical responses
in combination with DC therapy. Alterations in Treg numbers upon
treatment could not be correlated with clinical outcome, although
nTreg frequencies at baseline were predictive of clinical response.71,73
However, further research is needed to determine whether this is
also observed in other malignancies and combination therapies
(Figure 1B).
MDSCs. Numerous chemotherapeutics, such as gemcitabine, 5-FU,
cisplatin, and docetaxel, have been shown to speciﬁcally deplete
MDSCs.12,73,117,118 Furthermore, docetaxel possibly improves immu-
nostimulatory effects of total MDSCs by skewing them into a more
favorable pro-inﬂammatory and migratory phenotype (CCR2,
CCR5, CX3CR1, and CCR7) rather than an immunosuppressive
phenotype.133 This indicates that chemotherapeutics not only deplete
immunoregulatory cells but also can change the phenotype of immu-
nosuppressive cells. In contrast to the above-described chemothera-
peutics, cyclophosphamide increases the amount of speciﬁc pMDSCs,
but not mMDSCs, in the peripheral blood of mice and human.134 The
increase in pMDSCs induced by cyclophosphamide can be
Table 1. Overview of Clinical Trials Combining moDC Therapy with Chemotherapy
Disease
Loading
Material
for DCs
Maturation
Cocktail
CTX (+ Other
Additional
Treatments)
Immunomodulatory
Effecta
Immunological
Rationaleb
CTX
Immune
Readoutc
DC Therapy
Immune Readout d n CO
CO Corresponding
to IR Reference
Glioblastoma
autologous
tumor lysate
TNF-a, IFN-a
and POLI I:C
RTX + TMZ
75 mg/m2TMZ
200 mg/m2
Treg depletion none none 8/25 pos ELISPOT 31
PFS 12.7
OS 23.4m
no 63
Pancreatic
cancer
WT1 peptide
OK-432 and
PGE2
S1 or S1 +
gemcitabine
dose not stated
Treg depletion
MDSC depletion
none none 7/8 pos ELISPOT 8
4 PD
4 alive
2 years p t-
treatmen
pos ELISPOT
correlated to
2-year OS
125
Pancreatic
cancer
WT1-I, -II,
I/II peptide
OK-432 and
PGE2
gemcitabine
1000 mg/m2
Treg depletion,
MDSC depletion
none none 4/11 pos DTH 10 7 SD, 3 P
pos DTH positively
correlated with PFS
72
Glioblastoma
autologous
tumor lysate
monocyte-
derived
conditioned
medium (MCM)
TMZ 150-200 mg Treg depletion none none
2/9 pos ELISPOT
0 pos DTH
14
2 PR, 3 S
4 PD
median
OS 23m
no 62
Esophageal
cancer
WT1 peptide
OK-432
andPG-E2
DTX 50 mg/m2
Treg depletion,
MDSC skewing,
ICD induction
non-speciﬁc
immune
enhancement
none
5/8 pos ELISPOT
3/7 pos DTH
3/7 pos tetramer
5/8 pos HLA
10 10 PD no 65
Melanoma
WT1 peptide,
gp100
tyrosinase,
MAGE-A3 or
MAGE-A2
Matured with
OK-432 and
PG-E2
carboplatin
(AUC 5) and
paclitaxel
(175 mg/m2)
Treg depletion
Treg depletion
and decrease
IL-10 and
TGF-b secretion
none 4/9 pos ELISPOT 9
1 PR, 4 S
5 PD
OS 12m
PFS 2,3m
no 124
Prostate cancer
PSA, PAP
mRNA
TNF-a IL-1B,
IL-6, PGE2
DTX 75mg/m2
Treg depletion,
MDSC skewing,
ICD induction
MDSC depletion
and ICD
DC + DTX:
decrease in
MDSC
9/18 pos ELISPOT
5/18 pos DTH
19 DTX
21 DTX +
DC
no differ ce
in PFS
and OS
decreasing levels
of MDSC were
correlated to
better PFS
64
Melanoma
p53, survivin,
and hTERT
mRNA
TNF-a IL-1B,
IL-6, PGE2
cyclophosphamide
50 mg
Treg depletion, ICD
induction
Treg depletion
CD4+
T-cell
depletion
6/17 pos ELISPOT 22
9 SD, 13
OS 10,4m
PFS 3,1m
no 127
Mesothelioma
autologous
tumor lysate
PGE2 TNF-a
IL-1B IL-6
cyclophosphamide
2x50 mg
Treg depletion,
inducing ICD
Treg depletion
Treg
depletion
8/10 pos DTH 10
1 CR, 4 S ,
NA 3,PD
no 71
Prostate
cancer
killed LNCaP
prostate
cancer cells
poly I:C
50 mg
cyclophosphamide,
75 mg/m2 DTX
Treg depletion,
MDSC skewing,
ICD induction
Treg depletion,
enhancement of
T and NK cell
activation
Treg
depletion
increased CD8+
T-cells, increased
PSA- speciﬁc
IFN- g production
24 OS 19m no 132
Melanoma
autologous
pulsed DC
TNF-a IL-1B,
IL-6 PGE2
TMZ 75mg/m2 (IL-
2)3,000,000 IU/day
Treg depletion Treg depletion
Treg
depletion
9/17 pos DTH 17
1 PR, 6 S
10 PD
no 74
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Reviewcounteracted by the addition of chemotherapeutics targeting MDSCs,
as combining cyclophosphamide and gemcitabine treatment
decreased both Treg and GR1high MDSC numbers and reduced tumor
growth.135
One study in patients with stage IV pancreatic ductal adenocarci-
noma treated with WT1-loaded DC therapy and gemcitabine
(1,000mg/m2 three times every 28 days) showed that combining these
treatments is safe and feasible.72 They also found a positive correla-
tion between DTH skin testing and PFS. Unfortunately, MDSC
numbers were not assessed in this study, so it remains inconclusive
whether gemcitabine administration in combination with DC therapy
affected MDSC numbers in these patients.
In a clinical study in patients with metastasized adenocarcinoma of
the prostate, docetaxel (75 mg/m2 every 3 weeks) monotherapy was
compared to combined treatment of docetaxel with DCs transfected
with mRNAs encoding PAP (prostate acidic phosphatase) and PSA
(prostate-speciﬁc antigen).64 There was no signiﬁcant difference in
OS and PFS between both treatment arms. Patients with decreased
MDSC frequencies in cryopreserved PBMCs upon treatment had a
longer PFS as compared to patients with increasing frequencies of
MDSCs upon treatment. A decrease of MDSCs in cryopreserved
PBMCs was only observed 6 weeks after the start of combination
therapy, but not upon docetaxel monotherapy, which suggests that
docetaxel monotherapy is not sufﬁcient to decrease MDSCs in pe-
ripheral blood.64 Paradoxically, a preclinical study observed a
decrease in total MDSC numbers upon treatment with docetaxel
monotherapy.133 Additionally, docetaxel treatment skewed total
MDSCs toward a more pro-inﬂammatory phenotype in a preclinical
study (Figure 1C).133 Characterization of MDSCs remains chal-
lenging due to a lack of speciﬁc markers and the need to assess these
cell populations in freshly isolated blood, as especially pMDSCs are
lost upon cryopreservation.33 In addition, most clinical trials focus
on evaluating MDSC numbers rather than MDSC characteristics,
leading to a lack of evidence for the phenotypical switch of MDSCs
upon docetaxel treatment in humans.
ICD. Various chemotherapeutics, such as cyclophosphamide, oxa-
liplatin, paclitaxel, docetaxel, and anthracyclines, are able to induce
ICD (Figure 1E). The antineoplastic effects of these chemotherapeu-
tics are also dependent on ICD.136–139 Current monitoring of ICD
occurs via vaccination assays that are not applicable in clinical
trials.139 This limits the possibility for evaluation of ICD-induced
synergistic effects. Consequently, ICD is not often used as a ratio-
nale for combining chemotherapy and DC therapy (Table 1). A
phase III clinical study in patients with metastatic castration-resis-
tant prostate cancer comparing docetaxel treatment combined
with DC therapy and docetaxel monotherapy has ﬁnished;
accrual end results are awaited (ClinicalTrials.gov: NCT02111577).
Hopefully, immunological data will lead to a better under-
standing of the immunomodulatory effects of docetaxel. A phase
III trial in glioma patients evaluates the additional effect of DC
therapy to current treatment consisting of TMZ and radiotherapy
www.moleculartherapy.org
Review(ClinicalTrials.gov: NCT03548571). The addition of a DC mono-
therapy arm to both these studies could have revealed the synergis-
tic effect of docetaxel and TMZ on DC therapy.
Combining Radiotherapy with DC Therapy
Radiotherapy has been used as local tumor treatment for the last cen-
tury. Recently, radiotherapy was also found to affect non-radiated tu-
mor lesions, which is called the abscopal effect. This suggests systemic
effects of radiotherapy that can be explained by the upregulation of
radiation-induced double-stranded DNA in the cytosol, which serves
as a DAMP for the instigation of ICD. Subsequently, the secretion of
type I IFNs by tumor cells will attract cDC1s to the tumor site, which
can engulf the released tumor antigens and initiate an immune
response.16,140 Therefore, radiation-induced ICD can act as in situ
vaccination.
Apart from inducing ICD, radiation induces the upregulation of
adhesion molecules on the vascular endothelium of tumor cells,
which enables T cell inﬁltration141 (Figure 1E). Furthermore, a
non-lethal radiotherapy dosage increases surface expression of ﬁrst
apoptosis signal (Fas) ligand, carcinoembryonic antigen, and major
histocompatibility complex I (MHCI) on tumor cells, enabling
tumor-speciﬁc CD8+ T cells to recognize the tumor cells and
exert their cytotoxic effects.142 Together, these immunomodulatory
effects are hypothesized to be responsible for the abscopal effect.143
However, the theoretical immunomodulatory effect of radiotherapy
lacks clinical support, as a recent review found only 46 reported
cases of abscopal effect from 1969 to 2004.144 This could be
dependent on the irradiation dose used, radiation schedule, and
lack of additional immunostimulation. This is supported by a
recent study in breast and colorectal tumor-bearing mice, where
different radiation doses were compared in combination with CI.
Here they found that repetitive radiation at a low dose (5–8 Gy)
was more effective than a high (20-Gy) single dose.145,146 High-
dose radiation is thought to indirectly downregulate cytosolic
double-stranded DNA (dsDNA) and, thus, inhibit radiation-depen-
dent ICD.16
Clinical Trials Combining DC Therapy with Radiotherapy
In a phase I clinical trial, 14 patients with advanced hepatoma
received immature DC therapy followed by 8-Gy radiotherapy. The
clinical results varied, with 2 PRs, 4 minor responses, 3 SD, and
4 PD.147 Seven of ten immunologically evaluated patients developed
an IFN-g ELISPOT response upon treatment, which did not correlate
with clinical response.
In an observational study, patients with esophageal cancer receiving
autologous tumor lysate-loaded DC therapy in combination with
concurrent radiotherapy (60 Gy) were compared to radiotherapy
alone. The 2-year survival was signiﬁcantly improved upon combina-
tion therapy (67.8%) as compared to single radiotherapy treatment
(33.3%).148 Additionally, in patients with metastatic solid tumors,
radiotherapy (35 Gy) combined with in situ DC therapy using GM-
CSF administration, induced an abscopal effect in 11 of 41 patients,which was signiﬁcantly higher compared to abscopal effects induced
by radiotherapy alone.149
These data suggest that regional radiotherapy can act synergistically
when combined with DC therapy. The synergy likely depends on
the release of tumor antigen that boosts the anti-tumor immune
response, and it should be further investigated in ongoing clinical tri-
als. A recently registered trial for patients with metastatic melanoma
will evaluate the additional effect of different immunostimulatory
agents, including radiotherapy (24–32 Gy), to autologous tumor
lysate-loaded DC therapy (ClinicalTrials.gov: NCT01973322).150
Additionally, the effect of sipuleucel-T therapy combined with stereo-
tactic ablative body radiation in patients with metastatic castration-
resistant prostate cancer will be observed in a single-arm study
(ClinicalTrials.gov: NCT01818986). These studies will allow further
investigation into the exact immunological mechanism of action of
radiotherapy combined with DC therapy.
Other Combination Strategies: Targeting TAMs
Immunoinhibitory TAMs are abundant in many solid tumors.151,152
These TAMs can be either depleted via colony-stimulating factor 1
receptor (CSF-1R) blockade or skewed into an immunostimulatory
M1 phenotype by CD40 agonistic mAb.153–159 CSF-1R blockade
increased the efﬁcacy of chemotherapy in pancreatic tumor-bearing
mice.160 In glioblastoma tumor-bearing mice, TAM depletion by
CSF-1R monotherapy induced tumor reduction and increased sur-
vival.161 In contrast, in a mesothelioma mouse model, CSF-1R kinase
inhibitor PLX3397 (pexidartinib)-mediated TAM depletion as mono-
therapy did not improve survival.153 However, when pexidartinib
treatment was combined with DC therapy, improved survival was
observed when compared to both monotherapies, which was accom-
panied by increased numbers of proliferating T cells and effector
T cells.153
These studies indicate that TAM depletion can improve the immuno-
suppressive character of the TME and, thereby, act synergistically
when combined with DC therapy. In addition to TAM depletion,
skewing TAMs toward an immunostimulatory M1 phenotype using
CD40 mAb may even hold more clinical potential, as CD40 mAb-
activated macrophages in pancreatic cancer inﬁltrate the tumor and
facilitate tumor stroma depletion.162 Especially in tumors with dense
stroma, targeting the stroma indirectly through macrophage skewing
could facilitate and improve tumor-speciﬁc T cell inﬁltration upon
DC therapy (Figure 1D).
Future Perspectives
Currently, most clinical trials that combine DC therapy with other
treatments, such as chemotherapy, radiotherapy, or CI, often lack
immunological rationale. This is likely due to already existing regis-
trations of these treatments based on other rationales, leading to
the mandatory use of certain therapies in speciﬁc dosages and sched-
ules. In an experimental setting, a lack of consistency in dosing and
schedule of treatments complicates the comparison of both immuno-
logical responses and clinical efﬁcacy between different studies. ForMolecular Therapy: Oncolytics Vol. 13 June 2019 75
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Reviewexample, a “metronomic” dosage of cyclophosphamide varies from
2 50 mg/day to 100 mg/day between different studies,71,127 whereas
Treg depletion is dependant on the dose and schedule of chemo-
therapy.29 Separate studies should be performed to analyze the immu-
nomodulatory effects of chemotherapy, radiotherapy, targeted thera-
pies, and immunotherapies alone. During these studies, adequate
reports of the used methods and analyzation strategies are necessary
to facilitate the standardization of type and timing of immunomoni-
toring assays.163 This will create the possibility to replicate and subse-
quently compare the immunomodulatory effects between studies,
and, ﬁnally, it leads to a better understanding of the immunomodu-
latory effects of monotherapies.115With this knowledge, speciﬁc ther-
apies with the right dosing can be combined with DC therapy based
on the TME characteristics (Figure 1).
Variations in DC therapy, in terms of antigen loading, maturation,
use of different DC subsets, dosage per injection, and the interval
or total amount of vaccinations, make it difﬁcult to compare clinical
studies with each other. Adequate immunomonitoring in DC ther-
apy is mandatory to create the possibility to compare studies and
evaluate the effects of different antigen-loading methods, maturation
cocktails, and administration schedules or injection sites. Addition-
ally, registration of DC therapies will enable the investigation of
clinical efﬁcacy of DC therapy in combination with other treatments
as compared to DC monotherapy. This will inevitably lead to an
increase in the number of randomized trials and rapid release
and approval for registration of immunomodulatory therapies in
combination with DC therapy. To date, sipuleucel-T is the only
registered DC therapy.47 Phase III trials that could eventually
lead to the registration of DC therapy are ongoing for melanoma
(ClinicalTrials.gov: NCT02993315), glioblastoma (ClinicalTrials.gov:
NCT03548571), mesothelioma (ClinicalTrials.gov: NCT03610360),
and colorectal cancer (ClinicalTrials.gov: NCT02503150).
Hopefully, trials combining DC therapy with other therapies, based
on a solid rationale and performed with adequate immunomonitor-
ing and uniformity in administration schedules, will lead to the regis-
tration of already existing treatment modalities for new purposes. In
this way, chemotherapeutics, radiotherapy, CIs, or other targeted
therapies can be used as off-the-shelf, affordable immunomodulating
agents to support DC therapy in a personalized manner. To accom-
plish this, intensive cooperation between clinicians and basic scien-
tists will be needed.
Other targets for cancer therapy, such as additional co-inhibitory
molecules, co-stimulatory molecules, or even targeted therapies
such as indoleamine 2,3-dioxygenase (IDO), are upcoming. These
targets could all hypothetically be used as immunomodulators in
the future. However, we have to be cautious as some of these therapies
are not yet found to be effective in phase III trials in humans.164 In the
process of proving clinical efﬁcacy of these drugs, immunomonitor-
ing data should already be obtained in an earlier stage, whereby the
immunomodulatory effects of these therapies are known before
registration.76 Molecular Therapy: Oncolytics Vol. 13 June 2019Conclusions
Apart from improving DC therapy itself, inﬂuencing the immuno-
suppressive character of the TME by targeting immune cells, such
as Tregs, MDSCs, or TAMs, with already registered therapies could
improve response rates upon DC therapy. To accomplish this, phase
III clinical trials are urgently required that investigate clinical efﬁcacy
upon DC therapy combined with other treatments and registration of
DC therapy for multiple malignancies. Additionally, elucidating the
underlying immunological mechanism of these synergistic effects
upon combination therapy will further boost the combination of
DC therapy with other therapies. A better understanding will also
lead to personalized combination therapy, wherein DC therapy will
be combined with other therapies based on composition of the
TME, the expression of inhibitory molecules on the surface of tumor
and immunosuppressive cells, and tumor mutational burden
(Figure 1).
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